2026 Milestones in Focus as Sionna Therapeutics Pursues NBD1 Stabilization for CFTR

• SION-719: Topline data from the Phase 2a trial are expected for mid this year.
• SION-451: Phase 1 combination study results are also scheduled for mid-2026.
• Financial position: The liquidity reported through Q3 2025 is sufficient to fund operations into 2028, sustaining ongoing programs beyond the key data releases in the summer of 2026.

Innovative Stabilization of the CFTR Protein
Sionna’s research program centers on compact molecules that stabilize the NBD1 segment of CFTR, the region implicated by the F508del mutation in cystic fibrosis. By reinforcing this part of the protein, the company aims to push CFTR function closer to normal, with the goal of translating into better clinical outcomes for patients.

Compared with existing therapies, Sionna is pursuing a differentiated path. The candidate SION-719 is being explored as a potential add-on therapy to the current standard of care for adults. Upcoming data from the PreciSION CF study are anticipated to reveal whether this novel NBD1 stabilizer can deliver the anticipated safety and efficacy in a real-world clinical setting.

Should investors sell immediately? Or is it worth buying Sionna Therapeutics?

Financial Reach Through 2028
Beyond scientific progress, financial stability remains a critical driver for a biotech venture like Sionna. The company’s balance sheet as of the third quarter of 2025 shows a cash position that funds operations through 2028, ensuring the continuation of its clinical programs even beyond the major data readouts planned for summer 2026.

investor attention is increasingly focused on turning this pipeline into tangible value. The results from SION-719 and SION-451 will significantly influence how the company’s scientific platform and execution capabilities are perceived. The mid-2026 study data are set to serve as the next meaningful inflection point in evaluating the equity.